Zydus Cadila gets final approval from USFDA for Piroxicam Capsules

19 Jul 2018 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Piroxicam Capsules USP (US RLD - Feldene Capsules) in strengths of 10 mg and 20 mg. It is a non-steroidal anti-inflammatory drug indicated for symptomatic treatment of osteoarthritis and rheumatoid arthritis. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

In line with this, the group now has 209 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

867.80 -16.20 (-1.83%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×